



P.17019/01/2022-PvPI

Indian Pharmacopoeia Commission

National Coordination Centre-Pharmacovigilance Programme of India

(Ministry of Health & Family Welfare, Govt. of India)

Email: signal.pvpi-ipc@gov.in, lab.ipc@gov.in, Website: www.ipc@gov.in, Tel. No. 0120-2783400

Sector - 23, Raj Nagar,  
Ghaziabad - 201002, U.P.

Dated: 30<sup>th</sup> May, 2022

### Monthly Drug Safety Alert

The preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

Table

Sl. No	Suspected Drug	Indication	Adverse Drug Reaction
1	Itraconazole	<ul style="list-style-type: none"><li>Systemic aspergillosis and candidiasis, cryptococcosis, sporotrichosis, Paracoccidioidomycosis, blastomycosis and other rarely occurring systemic or tropical mycoses.</li><li>Empiric therapy of febrile neutropenic patients with suspected fungal infections.</li></ul>	Symmetrical Drug Related- Intertriginous and Flexural Exanthema (SDRIFE)

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “**ADR PvPI App**” and **PvPI Helpline No. 1800-180-3024.**